{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T10:31:11Z","timestamp":1782556271363,"version":"3.54.5"},"reference-count":141,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2018ZX10715004"],"award-info":[{"award-number":["2018ZX10715004"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31571368"],"award-info":[{"award-number":["31571368"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31871324"],"award-info":[{"award-number":["31871324"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81730064"],"award-info":[{"award-number":["81730064"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2018RS3006"],"award-info":[{"award-number":["2018RS3006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.bcp.2021.114485","type":"journal-article","created":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T16:31:22Z","timestamp":1613838682000},"page":"114485","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Life-long passion for antiviral research and drug development: 80th birthday of Prof. Dr. Erik De Clercq"],"prefix":"10.1016","volume":"185","author":[{"given":"Guangdi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2868-0787","authenticated-orcid":false,"given":"Tingting","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3706-7404","authenticated-orcid":false,"given":"Weijie","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bcp.2021.114485_b0005","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the Past 50 Years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"issue":"1","key":"10.1016\/j.bcp.2021.114485_b0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/17425255.2020.1711884","article-title":"Clinical significance of chemokine receptor antagonists","volume":"16","author":"Miao","year":"2020","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.bcp.2021.114485_b0015","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.bcp.2018.05.010","article-title":"Tanovea(R) for the treatment of lymphoma in dogs","volume":"154","author":"De Clercq","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2021.114485_b0020","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1128\/jvi.2.9.878-885.1968","article-title":"Antiviral activity of polyacrylic and polymethacrylic acids. I. Mode of action in vitro","volume":"2","author":"De Somer","year":"1968","journal-title":"J. Virol."},{"issue":"9","key":"10.1016\/j.bcp.2021.114485_b0025","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1128\/jvi.2.9.886-893.1968","article-title":"Antiviral activity of polyacrylic and polymethacrylic acids. II. Mode of action in vivo","volume":"2","author":"De Somer","year":"1968","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114485_b0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0304-3835(79)90017-X","article-title":"Suramin: A potent inhibitor of the reverse transcriptase of RNA tumor viruses","volume":"8","author":"De Clercq","year":"1979","journal-title":"Cancer Lett."},{"issue":"4671","key":"10.1016\/j.bcp.2021.114485_b0035","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1126\/science.6091268","article-title":"Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III","volume":"226","author":"Mitsuya","year":"1984","journal-title":"Science"},{"issue":"8456","key":"10.1016\/j.bcp.2021.114485_b0040","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0140-6736(85)90002-9","article-title":"Effects of suramin on HTLV-III\/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: Clinical pharmacology and suppression of virus replication in vivo","volume":"326","author":"Broder","year":"1985","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bcp.2021.114485_b0045","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1073\/pnas.76.6.2947","article-title":"(E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent","volume":"76","author":"De Clercq","year":"1979","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6249","key":"10.1016\/j.bcp.2021.114485_b0050","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/bmj.281.6249.1178","article-title":"Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine in severe herpes zoster","volume":"281","author":"De Clercq","year":"1980","journal-title":"Br. Med. J."},{"issue":"4341","key":"10.1016\/j.bcp.2021.114485_b0055","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1126\/science.200.4341.563","article-title":"(S)-9-(2,3-Dihydroxypropyl)adenine: An aliphatic nucleoside analog with broad-spectrum antiviral activity","volume":"200","author":"De Clercq","year":"1978","journal-title":"Science"},{"issue":"5766","key":"10.1016\/j.bcp.2021.114485_b0060","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/285542a0","article-title":"Isolation and structure of a human fibroblast interferon gene","volume":"285","author":"Derynck","year":"1980","journal-title":"Nature"},{"issue":"5779","key":"10.1016\/j.bcp.2021.114485_b0065","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/287193a0","article-title":"Expression of human fibroblast interferon gene in Escherichia coli","volume":"287","author":"Derynck","year":"1980","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bcp.2021.114485_b0070","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1021\/jm00358a029","article-title":"Synthesis and antiviral activity of water-soluble esters of acyclovir [9-[(2-hydroxyethoxy)methyl]guanine]","volume":"26","author":"Colla","year":"1983","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2021.114485_b0075","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1001\/archopht.1984.01040030118049","article-title":"Topical treatment of experimental herpes simplex keratouveitis with 2'-O-glycylacyclovir A water-soluble ester of acyclovir","volume":"102","author":"Maudgal","year":"1984","journal-title":"Arch. Ophthalmol."},{"issue":"6087","key":"10.1016\/j.bcp.2021.114485_b0080","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/323464a0","article-title":"A novel selective broad-spectrum anti-DNA virus agent","volume":"323","author":"De Clercq","year":"1986","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2021.114485_b0085","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0006-291X(87)90460-8","article-title":"Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro","volume":"142","author":"Baba","year":"1987","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.bcp.2021.114485_b0090","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/0006-291X(89)92756-3","article-title":"Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative","volume":"165","author":"Baba","year":"1989","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"12","key":"10.1016\/j.bcp.2021.114485_b0095","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1021\/jm00132a002","article-title":"A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine","volume":"32","author":"Miyasaka","year":"1989","journal-title":"J. Med. Chem."},{"issue":"6257","key":"10.1016\/j.bcp.2021.114485_b0100","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/343470a0","article-title":"Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives","volume":"343","author":"Pauwels","year":"1990","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.bcp.2021.114485_b0105","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1021\/jm040840e","article-title":"In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine)","volume":"48","author":"Janssen","year":"2005","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2021.114485_b0110","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.bcp.2012.03.024","article-title":"Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination era","volume":"84","author":"De Clercq","year":"2012","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2021.114485_b0115","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/AAC.37.2.332","article-title":"Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine","volume":"37","author":"Balzarini","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.bcp.2021.114485_b0120","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/AAC.42.7.1568","article-title":"Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice","volume":"42","author":"Naesens","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"issue":"22","key":"10.1016\/j.bcp.2021.114485_b0125","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1021\/jm990346o","article-title":"Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base","volume":"42","author":"McGuigan","year":"1999","journal-title":"J. Med. Chem."},{"issue":"26","key":"10.1016\/j.bcp.2021.114485_b0130","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1021\/jm000210m","article-title":"Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain","volume":"43","author":"McGuigan","year":"2000","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2021.114485_b0135","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/med.10035","article-title":"Highly potent and selective inhibition of varicella-zoster virus replication by bicyclic furo[2,3-d]pyrimidine nucleoside analogues","volume":"23","author":"De Clercq","year":"2003","journal-title":"Med. Res. Rev."},{"issue":"12","key":"10.1016\/j.bcp.2021.114485_b0140","doi-asserted-by":"crossref","first-page":"5286","DOI":"10.1073\/pnas.89.12.5286","article-title":"Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event","volume":"89","author":"De Clercq","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.bcp.2021.114485_b0145","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1128\/AAC.38.4.668","article-title":"Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100","volume":"38","author":"De Clercq","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.bcp.2021.114485_b0150","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrd1134","article-title":"The bicyclam AMD3100 story","volume":"2","author":"De Clercq","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.bcp.2021.114485_b0155","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.bcp.2008.12.014","article-title":"The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil)","volume":"77","author":"De Clercq","year":"2009","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2021.114485_b0160","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.pharmthera.2010.08.009","article-title":"Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil) and potential of other CXCR4 antagonists as stem cell mobilizers","volume":"128","author":"De Clercq","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2021.114485_b0165","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3389\/fimmu.2015.00276","article-title":"AMD3100\/CXCR4 Inhibitor","volume":"6","author":"De Clercq","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2021.114485_b0170","doi-asserted-by":"crossref","DOI":"10.1177\/2040206619829382","article-title":"Mozobil(R) (Plerixafor, AMD3100), 10 years after its approval by the US, Food and Drug Administration","volume":"27","author":"De Clercq","year":"2019","journal-title":"Antiviral Chem. Chemother."},{"issue":"5\u20136","key":"10.1016\/j.bcp.2021.114485_b0175","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0166-3542(87)80004-9","article-title":"Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines","volume":"8","author":"De Clercq","year":"1987","journal-title":"Antiviral Res."},{"issue":"10","key":"10.1016\/j.bcp.2021.114485_b0180","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/17425255.2019.1673367","article-title":"Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment","volume":"15","author":"Wang","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"4","key":"10.1016\/j.bcp.2021.114485_b0185","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3390\/molecules26040923","article-title":"Drug discovery of Nucleos(t)ide antiviral agents: Dedicated to Prof Dr. Erik De Clercq on Occasion of His 80th Birthday","volume":"26","author":"Li","year":"2021","journal-title":"Molecules"},{"issue":"7","key":"10.1016\/j.bcp.2021.114485_b0190","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1067","article-title":"Harnessing host-virus evolution in antiviral therapy and immunotherapy","volume":"8","author":"Heaton","year":"2019","journal-title":"Clin Transl Immunol."},{"issue":"3","key":"10.1016\/j.bcp.2021.114485_b0195","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1128\/AAC.42.3.612","article-title":"Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA","volume":"42","author":"Robbins","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/j.bcp.2021.114485_b0200","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00535-020-01698-4","article-title":"An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia","volume":"55","author":"Charlton","year":"2020","journal-title":"J. Gastroenterol."},{"issue":"4\u20137","key":"10.1016\/j.bcp.2021.114485_b0205","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1081\/NCN-100002496","article-title":"Metabolism of GS-7340, a novel phenyl monophosphoramidate intracellular prodrug of PMPA, in blood","volume":"20","author":"Eisenberg","year":"2001","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"5","key":"10.1016\/j.bcp.2021.114485_b0210","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1128\/AAC.49.5.1898-1906.2005","article-title":"Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue","volume":"49","author":"Lee","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.bcp.2021.114485_b0215","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/mol.108.045526","article-title":"Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases","volume":"74","author":"Birkus","year":"2008","journal-title":"Mol. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2021.114485_b0220","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.bcp.2012.12.011","article-title":"Antivirals: past, present and future","volume":"85","author":"De Clercq","year":"2013","journal-title":"Biochem. Pharmacol."},{"issue":"41","key":"10.1016\/j.bcp.2021.114485_b0225","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005146","article-title":"The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis","volume":"95","author":"Wang","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bcp.2021.114485_b0230","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijid.2020.01.035","article-title":"Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials","volume":"93","author":"Tao","year":"2020","journal-title":"Int. J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.bcp.2021.114485_b0235","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.bcp.2021.114485_b0240","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.bcp.2021.114485_b0245","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bcp.2017.11.023","article-title":"Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections","volume":"153","author":"De Clercq","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2021.114485_b0250","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"GS-US-320-0110 Investigators, Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.bcp.2021.114485_b0255","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"GS-US-320-0108 Investigators, Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.bcp.2021.114485_b0260","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S2468-1253(19)30421-2","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: A randomised, double-blind, phase 3, multicentre non-inferiority study","volume":"5","author":"Lampertico","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"12","key":"10.1016\/j.bcp.2021.114485_b0265","doi-asserted-by":"crossref","first-page":"e01426","DOI":"10.1128\/AAC.01426-20","article-title":"Population pharmacokinetics of intravenous and oral acyclovir and oral valacyclovir in pediatric population to optimize dosing regimens","volume":"64","author":"Abdalla","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7\u20138","key":"10.1016\/j.bcp.2021.114485_b0270","first-page":"518","article-title":"Evaluation of oral acyclovir therapy","volume":"19","author":"Fletcher","year":"1985","journal-title":"Drug Intell. Clin. Pharm."},{"issue":"7","key":"10.1016\/j.bcp.2021.114485_b0275","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1128\/AAC.01023-10","article-title":"Valacyclovir for herpes simplex encephalitis","volume":"55","author":"Pouplin","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.bcp.2021.114485_b0280","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/jac\/dky568","article-title":"Valaciclovir therapy for herpes encephalitis: Caution advised","volume":"74","author":"Bodilsen","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"10.1016\/j.bcp.2021.114485_b0285","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1128\/AAC.47.3.1072-1080.2003","article-title":"High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: Results of two randomized, placebo-controlled, multicenter studies","volume":"47","author":"Spruance","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.bcp.2021.114485_b0290","first-page":"105","article-title":"Valaciclovir for the suppression of recurrent genital HSV infection: A placebo controlled study of once daily therapy, International Valaciclovir HSV Study Group","volume":"73","author":"Patel","year":"1997","journal-title":"Genitourin. Med."},{"issue":"9","key":"10.1016\/j.bcp.2021.114485_b0295","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/01.olq.0000204723.15765.91","article-title":"Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding","volume":"33","author":"Wald","year":"2006","journal-title":"Sex. Transm. Dis."},{"issue":"7","key":"10.1016\/j.bcp.2021.114485_b0300","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/OLQ.0b013e31816d1f42","article-title":"HS2100275 Study Team, An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients","volume":"35","author":"Fife","year":"2008","journal-title":"Sex. Transm. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2021.114485_b0305","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1258\/0956462021924550","article-title":"International Valaciclovir HSV Study Group, Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials","volume":"13","author":"Conant","year":"2002","journal-title":"Int. J. STD AIDS"},{"issue":"7","key":"10.1016\/j.bcp.2021.114485_b0310","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1128\/AAC.39.7.1546","article-title":"Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults","volume":"39","author":"Beutner","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2021.114485_b0315","first-page":"CD011503","article-title":"Valacyclovir versus acyclovir for the treatment of herpes zoster ophthalmicus in immunocompetent patients","volume":"11","author":"Schuster","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"issue":"8","key":"10.1016\/j.bcp.2021.114485_b0320","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/00007435-199709000-00007","article-title":"The Valaciclovir International Herpes Simplex Virus Study Group, Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection Results of an international, multicenter, double-blind, randomized clinical trial","volume":"24","author":"Fife","year":"1997","journal-title":"Sex Transm. Dis."},{"issue":"2","key":"10.1016\/j.bcp.2021.114485_b0325","first-page":"110","article-title":"Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: A randomised, double blind clinical trial","volume":"73","author":"Bodsworth","year":"1997","journal-title":"Genitourin. Med."},{"issue":"6","key":"10.1016\/j.bcp.2021.114485_b0330","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1001\/jamainternmed.2017.0895","article-title":"Safety and Efficacy of antiviral therapy for prevention of cytomegalovirus reactivation in immunocompetent critically Ill Patients: A Randomized Clinical Trial","volume":"177","author":"Cowley","year":"2017","journal-title":"JAMA Intern. Med."},{"issue":"5","key":"10.1016\/j.bcp.2021.114485_b0335","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/tri.13085","article-title":"Impact of antiviral prophylaxis in adults Epstein-Barr Virus-seronegative kidney recipients on early and late post-transplantation lymphoproliferative disorder onset: A retrospective cohort study","volume":"31","author":"Ville","year":"2018","journal-title":"Transpl. Int."},{"issue":"9","key":"10.1016\/j.bcp.2021.114485_b0340","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.cmi.2020.04.006","article-title":"Management of cytomegalovirus infection in pregnancy: is it time for valacyclovir?","volume":"26","author":"Zammarchi","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"issue":"10253","key":"10.1016\/j.bcp.2021.114485_b0345","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0140-6736(20)31868-7","article-title":"Valaciclovir to prevent vertical transmission of cytomegalovirus after maternal primary infection during pregnancy: A randomised, double-blind, placebo-controlled trial","volume":"396","author":"Shahar-Nissan","year":"2020","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.bcp.2021.114485_b0350","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.bcp.2004.07.039","article-title":"Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster","volume":"68","author":"De Clercq","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114485_b0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-pharmtox-010510-100228","article-title":"A 40-year journey in search of selective antiviral chemotherapy","volume":"51","author":"De Clercq","year":"2011","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"5","key":"10.1016\/j.bcp.2021.114485_b0360","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1073\/pnas.78.5.2698","article-title":"On the mechanism of selective inhibition of herpesvirus replication by (E)-5-(2-bromovinyl)-2'-deoxyuridine","volume":"78","author":"Allaudeen","year":"1981","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.bcp.2021.114485_b0365","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1111\/j.1432-2277.2009.01045.x","article-title":"Epstein-Barr virus encephalitis after kidney transplantation and successful treatment with brivudine","volume":"23","author":"Lahmer","year":"2010","journal-title":"Transpl. Int."},{"issue":"4","key":"10.1016\/j.bcp.2021.114485_b0370","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1116","article-title":"Hypothesis: bipolar disorder is an Epstein-Barr virus-driven chronic autoimmune disease \u2013 Implications for immunotherapy","volume":"9","author":"Pender","year":"2020","journal-title":"Clin. Transl. Immunol."},{"issue":"9","key":"10.1016\/j.bcp.2021.114485_b0375","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s00432-011-1005-1","article-title":"RP101 (brivudine) binds to heat shock protein HSP27 (HSPB1) and enhances survival in animals and pancreatic cancer patients","volume":"137","author":"Heinrich","year":"2011","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114485_b0380","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1468-3083.2004.01119.x","article-title":"Collaborative Brivudin PHN Study Group, Brivudin compared with famciclovir in the treatment of herpes zoster: effects in acute disease and chronic pain in immunocompetent patients A randomized, double-blind, multinational study","volume":"19","author":"Wassilew","year":"2005","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114485_b0385","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0166-3542(03)00065-2","article-title":"Brivudin Herpes Zoster Study Group, Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicentered study","volume":"59","author":"Wassilew","year":"2003","journal-title":"Antiviral Res."},{"issue":"6","key":"10.1016\/j.bcp.2021.114485_b0390","doi-asserted-by":"crossref","first-page":"e626","DOI":"10.1097\/MJT.0000000000000436","article-title":"Comparison of famciclovir, valaciclovir, and brivudine treatments in adult immunocompetent patients with herpes zoster","volume":"25","author":"Yaldiz","year":"2018","journal-title":"Am. J .Ther."},{"issue":"2","key":"10.1016\/j.bcp.2021.114485_b0395","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1097\/01.qai.0000137371.80695.ef","article-title":"AMD3100 HIV Study Group, Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection","volume":"37","author":"Hendrix","year":"2004","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"8","key":"10.1016\/j.bcp.2021.114485_b0400","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1182\/blood-2003-02-0663","article-title":"Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist","volume":"102","author":"Liles","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bcp.2021.114485_b0405","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1537-2995.2005.04222.x","article-title":"Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist","volume":"45","author":"Liles","year":"2005","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.bcp.2021.114485_b0410","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1182\/blood-2007-12-130179","article-title":"Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4\/SDF-1 interaction","volume":"112","author":"Devine","year":"2008","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.bcp.2021.114485_b0415","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1200\/JCO.2008.20.7209","volume":"27","author":"DiPersio","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114485_b0420","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/trf.14426","article-title":"Plerixafor and granulocyte-colony-stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with non-Hodgkin's lymphoma: a randomized Phase 3 study","volume":"58","author":"Zhu","year":"2018","journal-title":"Transfusion"},{"issue":"23","key":"10.1016\/j.bcp.2021.114485_b0425","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"3102 Investigators, Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bcp.2021.114485_b0430","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMoa1808575","article-title":"Plerixafor for the Treatment of WHIM Syndrome","volume":"380","author":"McDermott","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.bcp.2021.114485_b0435","doi-asserted-by":"crossref","first-page":"6948","DOI":"10.1158\/1078-0432.CCR-19-1421","article-title":"Macrophage Exclusion after Radiation Therapy (MERT): A First in Human Phase I\/II Trial using a CXCR4 Inhibitor in Glioblastoma","volume":"25","author":"Thomas","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"46","key":"10.1016\/j.bcp.2021.114485_b0440","doi-asserted-by":"crossref","first-page":"28960","DOI":"10.1073\/pnas.2013644117","article-title":"CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response","volume":"117","author":"Biasci","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.bcp.2021.114485_b0445","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/ajh.25943","article-title":"Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed\/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients","volume":"95","author":"Borthakur","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.bcp.2021.114485_b0450","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3324\/haematol.2017.184788","article-title":"Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion","volume":"103","author":"Lagresle-Peyrou","year":"2018","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.bcp.2021.114485_b0455","first-page":"2805","article-title":"Evaluation of stem cell marker expression in canine B-Cell Lymphoma Cell Lines, B-Cell Lymphoma-generated Spheres and Primary Samples","volume":"35","author":"Liu","year":"2015","journal-title":"Anticancer Res."},{"issue":"34","key":"10.1016\/j.bcp.2021.114485_b0460","doi-asserted-by":"crossref","first-page":"21966","DOI":"10.1074\/jbc.273.34.21966","article-title":"Incorporation and excision of 9-(2-phosphonylmethoxyethyl)guanine (PMEG) by DNA polymerase delta and epsilon in vitro","volume":"273","author":"Kramata","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2021.114485_b0465","first-page":"195","article-title":"9-(2-phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine: a novel prodrug of 9-(2-phosphonylmethoxyethyl)guanine with improved antitumor efficacy and selectivity in choriocarcinoma-bearing rats","volume":"11","author":"Naesens","year":"1999","journal-title":"Oncol. Res."},{"issue":"4","key":"10.1016\/j.bcp.2021.114485_b0470","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/vco.12605","article-title":"Rabacfosadine for naive canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials","volume":"18","author":"Saba","year":"2020","journal-title":"Vet. Comp. Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2021.114485_b0475","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/jvim.12429","article-title":"Phase II evaluation of VDC-1101 in canine cutaneous T-cell lymphoma","volume":"28","author":"Morges","year":"2014","journal-title":"J. Vet. Intern. Med."},{"issue":"1","key":"10.1016\/j.bcp.2021.114485_b0480","doi-asserted-by":"crossref","first-page":"E76","DOI":"10.1111\/vco.12337","article-title":"Rabacfosadine for relapsed canine B-cell lymphoma: Efficacy and adverse event profiles of 2 different doses","volume":"16","author":"Saba","year":"2018","journal-title":"Vet. Comp. Oncol."},{"issue":"10","key":"10.1016\/j.bcp.2021.114485_b0485","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1158\/1078-0432.CCR-08-3113","article-title":"Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma","volume":"15","author":"Vail","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2021.114485_b0490","series-title":"Cold War Triangle: How scientists in East and West tamed HIV","author":"Loeckx","year":"2017"},{"issue":"7","key":"10.1016\/j.bcp.2021.114485_b0495","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1128\/AAC.32.7.1025","article-title":"Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents","volume":"32","author":"Pauwels","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"10.1016\/j.bcp.2021.114485_b0500","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1128\/AAC.32.12.1839","article-title":"(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication","volume":"32","author":"Snoeck","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.bcp.2021.114485_b0505","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1073\/pnas.86.1.332","article-title":"Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent","volume":"86","author":"Balzarini","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.bcp.2021.114485_b0510","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00002030-199101000-00003","article-title":"9-(2-Phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys","volume":"5","author":"Balzarini","year":"1991","journal-title":"AIDS"},{"issue":"6","key":"10.1016\/j.bcp.2021.114485_b0515","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.apsb.2015.09.001","article-title":"An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964\u20132014","volume":"5","author":"De Clercq","year":"2015","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.bcp.2021.114485_b0520","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.2147\/DDDT.S254754","article-title":"Danoprevir for the Treatment of Hepatitis C Virus Infection: Design Development, and Place in Therapy","volume":"14","author":"Miao","year":"2020","journal-title":"Drug Des. Devel Ther."},{"issue":"3","key":"10.1016\/j.bcp.2021.114485_b0525","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1128\/MMBR.00065-15","article-title":"HIV Genome-Wide Protein Associations: A Review of 30 Years of Research","volume":"80","author":"Li","year":"2016","journal-title":"Microbiol. Mol. Biol. Rev."},{"issue":"2","key":"10.1016\/j.bcp.2021.114485_b0530","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s12072-020-10015-3","article-title":"Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: A longitudinal cohort study","volume":"14","author":"Zhang","year":"2020","journal-title":"Hep. Intl."},{"issue":"9","key":"10.1016\/j.bcp.2021.114485_b0535","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1182","article-title":"Antibody seroconversion in asymptomatic and symptomatic patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","volume":"9","author":"Jiang","year":"2020","journal-title":"Clin Transl Immunol."},{"issue":"12","key":"10.1016\/j.bcp.2021.114485_b0540","doi-asserted-by":"crossref","first-page":"11296","DOI":"10.18632\/aging.103535","article-title":"Clinical characteristics of older and younger patients infected with SARS-CoV-2","volume":"12","author":"Zhou","year":"2020","journal-title":"Aging"},{"issue":"3","key":"10.1016\/j.bcp.2021.114485_b0545","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","article-title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)","volume":"19","author":"Li","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bcp.2021.114485_b0550","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.antiviral.2017.02.014","article-title":"Current therapy for chronic hepatitis C: The role of direct-acting antivirals","volume":"142","author":"Li","year":"2017","journal-title":"Antiviral Res."},{"issue":"1","key":"10.1016\/j.bcp.2021.114485_b0555","doi-asserted-by":"crossref","first-page":"27","DOI":"10.18632\/aging.202456","article-title":"Mortality risk of COVID-19 in elderly males with comorbidities: A multi-country study","volume":"13","author":"Li","year":"2020","journal-title":"Aging"},{"key":"10.1016\/j.bcp.2021.114485_b0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114114","article-title":"SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management","volume":"178","author":"Wu","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114485_b0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114169","article-title":"Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2","volume":"180","author":"Lisi","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114485_b0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114225","article-title":"Role of proteolytic enzymes in the COVID-19 infection and promising therapeutic approaches","volume":"182","author":"Gioia","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114485_b0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114296","article-title":"Repurposing existing drugs for the treatment of COVID-19\/SARS-CoV-2 infection: A review describing drug mechanisms of action","volume":"183","author":"Yousefi","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114485_b0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114316","article-title":"Detection of viral infections by innate immunity","volume":"183","author":"Carty","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114485_b0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.113777","article-title":"Antiviral drug discovery against arthritogenic alphaviruses: Tools and molecular targets","volume":"174","author":"Abdelnabi","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2021.114485_b0590","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1242","article-title":"Influenza, but not SARS-CoV-2, infection induces a rapid interferon response that wanes with age and diminished tissue-resident memory CD8(+) T cells","volume":"10","author":"Nguyen","year":"2021","journal-title":"Clin. Transl. Immunol."},{"issue":"12","key":"10.1016\/j.bcp.2021.114485_b0595","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1228","article-title":"Trained immunity as a novel approach against COVID-19 with a focus on Bacillus Calmette-Guerin vaccine: Mechanisms, challenges and perspectives","volume":"9","author":"Sohrabi","year":"2020","journal-title":"Clin. Transl. Immunol."},{"issue":"12","key":"10.1016\/j.bcp.2021.114485_b0600","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1224","article-title":"The Karolinska KI\/K COVID-19 Study Group, Innate lymphoid cell composition associates with COVID-19 disease severity","volume":"9","author":"Garcia","year":"2020","journal-title":"Clin Transl Immunol."},{"issue":"12","key":"10.1016\/j.bcp.2021.114485_b0605","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1219","article-title":"Rapid detection of SARS-CoV-2-specific memory T-cell immunity in recovered COVID-19 cases","volume":"9","author":"Lineburg","year":"2020","journal-title":"Clin. Transl. Immunol."},{"issue":"11","key":"10.1016\/j.bcp.2021.114485_b0610","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1218","article-title":"Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab","volume":"9","author":"Caballero","year":"2020","journal-title":"Clin. Transl. Immunol."},{"issue":"10","key":"10.1016\/j.bcp.2021.114485_b0615","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1198","article-title":"Intravenous immunoglobulin immunotherapy for coronavirus disease-19 (COVID-19)","volume":"9","author":"Galeotti","year":"2020","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.bcp.2021.114485_b0620","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114122","article-title":"Natural cardenolides suppress coronaviral replication by downregulating JAK1 via a Na(+)\/K(+)-ATPase independent proteolysis","volume":"180","author":"Yang","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114485_b0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114184","article-title":"COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials","volume":"180","author":"Chakraborty","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114485_b0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114057","article-title":"Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost","volume":"178","author":"Mohammed El Tabaa","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114485_b0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114215","article-title":"The inorganic polymer, polyphosphate, blocks binding of SARS-CoV-2 spike protein to ACE2 receptor at physiological concentrations","volume":"182","author":"Neufurth","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114485_b0640","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/2221148a0","article-title":"Requirement of a stable secondary structure for the antiviral activity of polynucleotides","volume":"222","author":"De Clercq","year":"1969","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2021.114485_b0645","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/226364a0","article-title":"Increase in antiviral activity of polynucleotides by thermal activation","volume":"226","author":"De Clercq","year":"1969","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2021.114485_b0650","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1126\/science.165.3898.1137","article-title":"Interferon induction increased through chemical modification of a synthetic polyribonucleotide","volume":"165","author":"De Clercq","year":"1969","journal-title":"Science"},{"key":"10.1016\/j.bcp.2021.114485_b0655","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1172\/JCI106374","article-title":"The role of interferon in the protective effect of a synthetic double-stranded polyribonucleotide against intranasal vesicular stomatitis virus challenge in mice","volume":"49","author":"De Clercq","year":"1970","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2021.114485_b0660","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev.me.21.020170.000313","article-title":"Current concepts of interferon and interferon induction","volume":"21","author":"De Clercq","year":"1970","journal-title":"Annu. Rev. Med."},{"issue":"1","key":"10.1016\/j.bcp.2021.114485_b0665","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1232","article-title":"Designing the next-generation therapeutic vaccines to cure chronic hepatitis B: Focus on antigen presentation, vaccine properties and effect measures","volume":"10","author":"Jansen","year":"2021","journal-title":"Clin. Transl. Immunol."},{"issue":"7","key":"10.1016\/j.bcp.2021.114485_b0670","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1149","article-title":"Mass cytometry reveals immune signatures associated with cytomegalovirus (CMV) control in recipients of allogeneic haemopoietic stem cell transplant and CMV-specific T cells","volume":"9","author":"McGuire","year":"2020","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.bcp.2021.114485_b0675","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bcp.2019.01.024","article-title":"Transport of ribavirin across the rat and human placental barrier: Roles of nucleoside and ATP-binding cassette drug efflux transporters","volume":"163","author":"Karbanova","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2021.114485_b0680","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114231","article-title":"Maraviroc reactivates HIV with potency similar to that of other latency reversing drugs without inducing toxicity in CD8 T cells","volume":"182","author":"Lopez-Huertas","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"23","key":"10.1016\/j.bcp.2021.114485_b0685","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bcp.2021.114485_b0690","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/jvh.12313","article-title":"Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial","volume":"22","author":"Hou","year":"2015","journal-title":"J. Viral Hepat."},{"issue":"9","key":"10.1016\/j.bcp.2021.114485_b0695","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.cgh.2018.11.001","article-title":"Efficacy and safety of besifovir dipivoxil maleate compared with tenofovir disoproxil fumarate in treatment of chronic hepatitis B virus infection","volume":"17","author":"Ahn","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.bcp.2021.114485_b0700","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089789","article-title":"Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings","volume":"9","author":"Pan","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bcp.2021.114485_b0705","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa035144","article-title":"Valacyclovir HSV Transmission Study Group, Once-daily valacyclovir to reduce the risk of transmission of genital herpes","volume":"350","author":"Corey","year":"2004","journal-title":"N. Engl. J. Med."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221000812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221000812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:06:01Z","timestamp":1777399561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295221000812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":141,"alternative-id":["S0006295221000812"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114485","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Life-long passion for antiviral research and drug development: 80th birthday of Prof. Dr. Erik De Clercq","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114485","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"114485"}}